Navigation Links
MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Date:5/13/2008

s in the quarter

resulted primarily from lower operating expenses in the first quarter

of 2008 compared to prior periods.

-- Other expenses for the first quarter of 2008 included a $7.4 million

noncash expense for the contractual fair value of warrants issued to

Deerfield Management in the fourth quarter of 2007. The Company

recorded a $2.1 million noncash warrant expense in the fourth quarter

of 2007. There were no such expenses in prior periods.

-- Net loss for the first quarter of 2008 was $13.8 million. This compares

to a net loss of $9.1 million in the fourth quarter of 2007, and $13.7

million in the first quarter of 2007. The net loss for the three months

ended March 31, 2008, was reduced by $0.2 million attributable to the

loss from noncontrolling interest in two companies affiliated with

Deerfield Management pursuant to the fourth quarter 2007 Keflex

transaction, resulting from MiddleBrook's consolidation of the two

affiliates under Financial Accounting Standards Board Interpretation

No. 46 (revised 2003) "Consolidation of Variable Interest Entities."

-- Net loss per share applicable to common stockholders for the first

quarter of 2008 was ($0.26), compared to a loss per common share of

($0.19) in the prior quarter and ($0.38) in the first quarter of 2007.

Per share figures were computed on the basis of an average of 53.3

million shares outstanding in the first quarter of 2008, 46.7 million

shares outstanding in the fourth quarter of 2007, and 36.4 million

shares outstanding in the first quarter of 2007.

-- Cash and marketable securities increased by $16.0 million during the

first quarter. Changes were composed of $19.9 million raised from the

sale of common stock and warrants, $1.5 million for non-cash expenses,

$0.7 million
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
(Date:7/28/2014)... July 28, 2014 Ticket Down ... tickets in Miami, FL at the Sun Life Stadium ... American football between Argentina and Brazil has is one that ... worldwide, more rivalries are forming on a consistent basis. ... a new height in the recent 2014 World Cup. ...
(Date:7/28/2014)... chronic medical conditions people have at retirement age, the ... claims. Since nearly four in five older ... Bloomberg School of Public Health in Baltimore said the ... are slowing in the United States. "Living with ... heart failure is now the norm and not the ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2
... Dr. Bijan Afar, a well-respected ... Many California residents are now able to benefit from the competent care of Dr. Afar and ... ... to announce the opening of his new office location in North Hollywood. All of the benefits ...
... ... Through Managing Electricity , ... Plano, TX (PRWEB) June 22, 2010 -- Vedero Software, a leading provider ... company Smart Energy Cloud. Under terms of the partnership agreement, Smart Energy Cloud ...
... tendencies until early adulthood, study finds , TUESDAY, June ... outlook are less likely to abuse alcohol, even if they ... Being religious does not, however, appear to prevent such abuse ... are reported in the September issue of Alcoholism: Clinical ...
... ... online medical image cloud computing service, today announced the following organizations will use ... ... June 22, 2010 -- SeeMyRadiology.com ( http://www.SeeMyRadiology.com ), Accelarad’s online medical ...
... ... line of “Eastern” products that address major physiological issues like sleep deprivation, stress, immune ... company,s supplements, oils and creams are comprised of a unique blend of natural ingredients ... ...
... the problem had higher levels of BPA, but study ... (HealthDay News) -- There may be more troubling news ... with polycystic ovary syndrome have higher levels of the ... ovaries of women with polycystic ovary syndrome (PCOS) develop ...
Cached Medicine News:Health News:Trusted Los Angeles Dentist, Dr. Bijan Afar, is Now Practicing in Hollywood Area 2Health News:Trusted Los Angeles Dentist, Dr. Bijan Afar, is Now Practicing in Hollywood Area 3Health News:Vedero Software Announces Partnership with Smart Energy Cloud for Automated Demand Response 2Health News:Vedero Software Announces Partnership with Smart Energy Cloud for Automated Demand Response 3Health News:Accelarad Announces Six New SeeMyRadiology.com Customers Seeking Fast, Secure and Innovative Medical Image Exchange Solution 2Health News:Launching Today: Herbal Destination, a New Kind of Company for Herbal Supplements, Oils and Creams 2Health News:Plastics Chemical BPA May Be Tied to Ovarian Cysts 2Health News:Plastics Chemical BPA May Be Tied to Ovarian Cysts 3
(Date:7/28/2014)... , July 28, 2014  A prospective study ... Sweden has validated the performance of ... and has associated volumetrically assessed breast density measurements ... Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the ... tool for widespread breast cancer risk assessment," was ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
(Date:7/28/2014)... MONACO , 28 luglio 2014 ResMed ... sviluppo di prodotti per la cura dei disturbi respiratori ... respiratorio, ha avuto un,ingiunzione permanente in Germania contro il ... che proibisce la vendita di apparecchiature da indossare in ... 210 e le maschere 220. La sentenza della Corte ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
... Diagnostics, Gene Expression Test Is the First to Receive FDA, ... ... Cancer Cases Annually, SUNNYVALE, Calif., July 31 Pathwork Diagnostics, ... Food and Drug Administration (FDA) has cleared its Pathwork(R),Tissue of Origin ...
... 31 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP) ( http://www.oramed.com ), ... will hold a conference call on August 6,2008 at ... Phase 2A clinical trials,of its flagship product, ORMD 0801, ... is focused on assessing the safety and efficacy,of ORMD ...
Cached Medicine Technology:FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2
... The NMP22 BladderChek Test is the only in-office ... of bladder cancer. The NMP22 BladderChek Test is ... single urine sample, that detects elevated levels of ... amounts of NMP22 protein in the urine. However, ...
... Kit is a quantitative microplate enzyme immunoassay that ... generally have very small amounts of NMP22 protein ... protein is often elevated in the urine of ... of the disease. The use of the NMP22 ...
... and urethral pressure profilometry. The catheter's ... to be filled while cystometry is ... catheter in the bladder for urodynamic ... standing or sitting. Supplied sterile in ...
... urethral pressure profilometry. Single lumen catheter ... the bladder and more accurate cystometric ... allows the bladder to be filled ... catheter construction allows cystometry and urethral ...
Medicine Products: